Session Details

Hot Line: Late-Breaking Clinical Trials 2
28 Aug 11:00 - 12:48 Miscellaneous Hot Line Barcelona - Main Auditorium
Chairpersons: Stephan ACHENBACH (Erlangen, Germany), Sarah Catherine CLARKE (Cambridge, United Kingdom)

Abstract Access slides, videos, reports online via ESC Congress 365 Other resources

Presentations list

Time
 
FP Nr
 
Title
 
Speakers
 
Related documents
11:003052SPYRAL HTN OFF-MED StudyMichael BOEHM (Homburg/Saar, Germany)
11:103053Discussant review: SPYRAL HTN OFF-MED StudyBryan WILLIAMS (London, United Kingdom)
11:153054Panel discussion. 
11:183055Apixaban vs conventional therapy in anticoagulation-naive patients with atrial fibrillation undergoing cardioversion: The EMANATE TrialMichael D EZEKOWITZ (Villanova, United States of America)
11:283056Discussant review:Apixaban vs conventional therapy in anticoagulation-naive patients with atrial fibrillation undergoing cardioversion: The EMANATE TrialJens Cosedis NIELSEN (Aarhus N, Denmark)
11:333057Panel discussion. 
11:363058An international multicenter clustered randomized trial to IMProve treatment with oral AntiCoagulanTs in Atrial FibrilationChristopher B GRANGER (Durham, United States of America)
11:463059Discussant review: An international multicenter clustered randomized trial to IMProve treatment with oral AntiCoagulanTs in Atrial FibrilationPaulus KIRCHHOF (Birmingham, United Kingdom)
11:513060Panel discussion. 
11:543061The Viborg Vascular randomised screening trialJes LINDHOLT (Odense, Denmark)
12:043062Discussant review: The Viborg Vascular randomised screening trialAndrew KATES (St. Louis, United States of America)
12:093063Panel discussion. 
12:123064Impact of a single or two dose regimen of inclisiran, a novel siRNA inhibitor to PCSK9 on time averaged reductions in LDL-C over 1 year. ORION 1Kausik K RAY (London, United Kingdom)
12:223065Discussant review: Impact of a single or two dose regimen of inclisiran, a novel siRNA inhibitor to PCSK9 on time averaged reductions in LDL-C over 1 year. ORION 1Philip BARTER (Sydney, Australia)
12:273066Panel discussion. 
12:303067DETermination of the role of OXygen in suspected Acute Myocardial InfarctionRobin HOFMANN (Stockholm, Sweden)
12:403068Discussant review: DETermination of the role of OXygen in suspected Acute Myocardial InfarctionDavid NEWBY (Edinburgh, United Kingdom)
12:453069Panel discussion.